Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Diagnostic value of retrospective PET-MRI fusion in head-and-neck cancer

Authors: Denys J Loeffelbein, Michael Souvatzoglou, Veronika Wankerl, Julia Dinges, Lucas M Ritschl, Thomas Mücke, Anja Pickhard, Matthias Eiber, Markus Schwaiger, Ambros J Beer

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

To assess the diagnostic value of retrospective PET-MRI fusion and to compare the results with side-by-side analysis and single modality use of PET and of MRI alone for locoregional tumour and nodal staging of head-and-neck cancer.

Methods

Thirty-three patients with head-and-neck cancer underwent preoperative contrast-enhanced MRI and PET/CT for staging. The diagnostic data of MRI, PET, side-by-side analysis of MRI and PET images and retrospective PET-MRI fusion were systematically analysed for tumour and lymph node staging using receiver operating characteristic (ROC) analysis. The results were correlated to the histopathological evaluation.

Results

The overall sensitivity/specificity for tumour staging for MRI, PET, side-by-side analysis and retrospective PET-MRI fusion was 79%/66%, 82%/100%, 86%/100% and 89%/100%, respectively. The overall sensitivity/specificity for nodal staging on a patient basis for MRI, PET, side-by-side analysis and PET-MRI fusion was 94%/64%, 94%/91%, 94%/82% and 94%/82%, respectively. MRI, PET, side-by-side analysis and retrospective image fusion were associated with correct diagnosis/over-staging/under-staging of N-staging in 70.4%/18.5%/11.1%, 81.5%/7.4%/11.1%, 81.5%/11.1%/7.4% and 81.5%/11.1%/7.4%, respectively.
ROC analysis showed no significant differences in tumor detection between the investigated methods. The Area Under the Curve (AUC) for MRI, PET, side-by-side analysis and retrospective PET-MRI fusion were 0.667/0.667/0.702/0.708 (p > 0.05). The most reliable technique in detection of cervical lymph node metastases was PET imaging (AUC: 0.95), followed by side-by-side analysis and retrospective image fusion technique (AUC: 0.941), which however, was not significantly better then the MRI (AUC 0.935; p > 0.05).

Conclusions

We found a beneficial use of multimodal imaging, compared with MRI or PET imaging alone, particular in individual cases of recurrent tumour disease. Side-by-side analysis and retrospective image fusion analysis did not perform significantly differently.
Appendix
Available only for authorised users
Literature
1.
Rumboldt Z, Gordon L, Bonsall R, Ackermann S: Imaging in head and neck cancer. Curr Treat Opt Oncol. 2006, 7 (1): 23-34. 10.1007/s11864-006-0029-2.CrossRef
2.
Argiris A, Karamouzis MV, Raben D, Ferris RL: Head and neck cancer. Lancet. 2008, 371 (9625): 1695-1709. 10.1016/S0140-6736(08)60728-X.CrossRefPubMed
3.
Lwin CT, Hanlon R, Lowe D, Brown JS, Woolgar JA, Triantafyllou A, Rogers SN, Bekiroglu F, Lewis-Jones H, Wieshmann H, Shaw RJ: Accuracy of MRI in prediction of tumour thickness and nodal stage in oral squamous cell carcinoma. Oral Oncol. 2012, 48 (2): 149-154. 10.1016/j.oraloncology.2011.11.002.CrossRefPubMed
4.
King AD, Tse GM, Yuen EH, To EW, Vlantis AC, Zee B, Chan AB, van Hasselt AC, Ahuja AT: Comparison of CT and MR imaging for the detection of extranodal neoplastic spread in metastatic neck nodes. Eur J Radiol. 2004, 52 (3): 264-270. 10.1016/j.ejrad.2004.03.004.CrossRefPubMed
5.
Offiah C, Hall E: Post-treatment imaging appearances in head and neck cancer patients. Clin Radiol. 2011, 66 (1): 13-24. 10.1016/j.crad.2010.09.004.CrossRefPubMed
6.
Ng SH, Chan SC, Yen TC, Liao CT, Lin CY, Tung-Chieh Chang J, Ko SF, Wang HM, Chang KP, Fan KH: PET/CT and 3-T whole-body MRI in the detection of malignancy in treated oropharyngeal and hypopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2011, 38 (6): 996-1008. 10.1007/s00259-011-1740-1.CrossRefPubMed
7.
Kim SK, Choi HJ, Park SY, Lee HY, Seo SS, Yoo CW, Jung DC, Kang S, Cho KS: Additional value of MR/PET fusion compared with PET/CT in the detection of lymph node metastases in cervical cancer patients. Eur J Cancer. 2009, 45 (12): 2103-2109. 10.1016/j.ejca.2009.04.006.CrossRefPubMed
8.
Goerres GW, Hany TF, Kamel E, von Schulthess GK, Buck A: Head and neck imaging with PET and PET/CT: artefacts from dental metallic implants. Eur J Nucl Med Mol Imaging. 2002, 29 (3): 367-370. 10.1007/s00259-001-0721-1.CrossRefPubMed
9.
Loeffelbein DJ, Mielke E, Buck AK, Kesting MR, Holzle F, Mucke T, Muller S, Wolff KD: Impact of nonhybrid 99mTc-MDP-SPECT/CT image fusion in diagnostic and treatment of oromaxillofacial malignancies. Mol Imaging Biol. 2010, 12 (1): 71-77. 10.1007/s11307-009-0231-2.CrossRefPubMed
10.
Nakamoto Y, Tamai K, Saga T, Higashi T, Hara T, Suga T, Koyama T, Togashi K: Clinical value of image fusion from MR and PET in patients with head and neck cancer. Mol Imaging Biol. 2009, 11 (1): 46-53. 10.1007/s11307-008-0168-x.CrossRefPubMed
11.
Czernin J, Allen-Auerbach M, Schelbert HR: Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med. 2007, 48 (Suppl 1): 78S-88S.PubMed
12.
Iyer NG, Clark JR, Singham S, Zhu J: Role of pretreatment 18FDG-PET/CT in surgical decision-making for head and neck cancers. Head Neck. 2010, 32 (9): 1202-1208. 10.1002/hed.21319.CrossRefPubMed
13.
Eiber M, Souvatzoglou M, Pickhard A, Loeffelbein DJ, Knopf A, Holzapfel K, Martinez-Moller A, Nekolla SG, Scherer EQ, Schwaiger M, Rummeny EJ, Beer AJ: Simulation of a MR-PET protocol for staging of head-and-neck cancer including Dixon MR for attenuation correction. Eur J Radiol. 2012, 81 (10): 2658-2665. 10.1016/j.ejrad.2011.10.005.CrossRefPubMed
14.
Loeffelbein DJ, Souvatzoglou M, Wankerl V, Martinez-Moller A, Dinges J, Schwaiger M, Beer AJ: PET-MRI fusion in head-and-neck oncology: current status and implications for hybrid PET/MRI. J Oral Maxillofac Surg. 2011, 70 (2): 473-483.CrossRefPubMed
15.
Kanda T, Kitajima K, Suenaga Y, Konishi J, Sasaki R, Morimoto K, Saito M, Otsuki N, Nibu K, Sugimura K: Value of retrospective image fusion of (18) F-FDG PET and MRI for preoperative staging of head and neck cancer: comparison with PET/CT and contrast-enhanced neck MRI. Eur J Radiol. 2013, 82 (11): 2005-2010. 10.1016/j.ejrad.2013.06.025.CrossRefPubMed
16.
Maza S, Taupitz M, Taymoorian K, Winzer KJ, Ruckert J, Paschen C, Raber G, Schneider S, Trefzer U, Munz DL: Multimodal fusion imaging ensemble for targeted sentinel lymph node management: initial results of an innovative promising approach for anatomically difficult lymphatic drainage in different tumour entities. Eur J Nucl Med Mol Imaging. 2007, 34 (3): 378-383. 10.1007/s00259-006-0223-2.CrossRefPubMed
17.
Somer EJ, Marsden PK, Benatar NA, Goodey J, O'Doherty MJ, Smith MA: PET-MR image fusion in soft tissue sarcoma: accuracy, reliability and practicality of interactive point-based and automated mutual information techniques. Eur J Nucl Med Mol Imaging. 2003, 30 (1): 54-62. 10.1007/s00259-002-0994-z.CrossRefPubMed
18.
Pechlivanis I, Scholz M, Harders A, Schmieder K: Occult sacral meningocele–a diagnostic challenge. Z Orthop Unfall. 2008, 146 (4): 468-470.CrossRefPubMed
19.
Seiboth L, Van Nostrand D, Wartofsky L, Ousman Y, Jonklaas J, Butler C, Atkins F, Burman K: Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer. Thyroid. 2008, 18 (2): 103-111. 10.1089/thy.2007.0135.CrossRefPubMed
20.
Robbins KT: Classification of neck dissection: current concepts and future considerations. Otolaryngol Clin N Am. 1998, 31 (4): 639-655. 10.1016/S0030-6665(05)70077-3.CrossRef
21.
Wolff KD, Follmann M, Nast A: The diagnosis and treatment of oral cavity cancer. Deutsches Arzteblatt Int. 2012, 109 (48): 829-835.
22.
Weber A, Schmid KW, Tannapfel A, Wittekind C: Changes in the TNM classification of head and neck tumors. Pathologe. 2010, 31 (5): 339-343. 10.1007/s00292-010-1302-5.CrossRefPubMed
23.
Rivelli V, Luebbers HT, Weber FE, Cordella C, Gratz KW, Kruse AL: Screening recurrence and lymph node metastases in head and neck cancer: the role of computer tomography in follow-up. Head Neck Oncol. 2011, 3: 18-10.1186/1758-3284-3-18.CrossRefPubMedPubMedCentral
24.
Kim SY, Roh JL, Kim JS, Ryu CH, Lee JH, Cho KJ, Choi SH, Nam SY: Utility of FDG PET in patients with squamous cell carcinomas of the oral cavity. Eur J Surg Oncol. 2008, 34 (2): 208-215. 10.1016/j.ejso.2007.03.015.CrossRefPubMed
25.
Roh JL, Yeo NK, Kim JS, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY: Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma. Oral Oncol. 2007, 43 (9): 887-893. 10.1016/j.oraloncology.2006.10.011.CrossRefPubMed
26.
Gupta T, Master Z, Kannan S, Agarwal JP, Ghsoh-Laskar S, Rangarajan V, Murthy V, Budrukkar A: Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011, 38 (11): 2083-2095. 10.1007/s00259-011-1893-y.CrossRefPubMed
27.
Isles MG, McConkey C, Mehanna HM: A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol. 2008, 33 (3): 210-222. 10.1111/j.1749-4486.2008.01688.x.CrossRefPubMed
28.
Ishikita T, Oriuchi N, Higuchi T, Miyashita G, Arisaka Y, Paudyal B, Paudyal P, Hanaoka H, Miyakubo M, Nakasone Y, Negishi A, Yokoo S, Endo K: Additional value of integrated PET/CT over PET alone in the initial staging and follow up of head and neck malignancy. Ann Nucl Med. 2010, 24 (2): 77-82. 10.1007/s12149-009-0326-5.CrossRefPubMed
29.
Gu DH, Yoon DY, Park CH, Chang SK, Lim KJ, Seo YL, Yun EJ, Choi CS, Bae SH: CT, MR, (18) F-FDG PET/CT, and their combined use for the assessment of mandibular invasion by squamous cell carcinomas of the oral cavity. Acta Radiol. 2010, 51 (10): 1111-1119. 10.3109/02841851.2010.520027.CrossRefPubMed
30.
Le Tourneau C, Velten M, Jung GM, Bronner G, Flesch H, Borel C: Prognostic indicators for survival in head and neck squamous cell carcinomas: analysis of a series of 621 cases. Head Neck. 2005, 27 (9): 801-808. 10.1002/hed.20254.CrossRefPubMed
31.
Mücke T, Wagenpfeil S, Kesting MR, Holzle F, Wolff KD: Recurrence interval affects survival after local relapse of oral cancer. Oral Oncol. 2009, 45 (8): 687-691. 10.1016/j.oraloncology.2008.10.011.CrossRefPubMed
32.
Fasunla AJ, Greene BH, Timmesfeld N, Wiegand S, Werner JA, Sesterhenn AM: A meta-analysis of the randomized controlled trials on elective neck dissection versus therapeutic neck dissection in oral cavity cancers with clinically node-negative neck. Oral Oncol. 2011, 47 (5): 320-324. 10.1016/j.oraloncology.2011.03.009.CrossRefPubMed
33.
Seitz O, Chambron-Pinho N, Middendorp M, Sader R, Mack M, Vogl TJ, Bisdas S: 18F-Fluorodeoxyglucose-PET/CT to evaluate tumor, nodal disease, and gross tumor volume of oropharyngeal and oral cavity cancer: comparison with MR imaging and validation with surgical specimen. Neuroradiology. 2009, 51 (10): 677-686. 10.1007/s00234-009-0586-8.CrossRefPubMed
34.
Krabbe CA, Dijkstra PU, Pruim J, van der Laan BF, van der Wal JE, Gravendeel JP, Roodenburg JL: FDG PET in oral and oropharyngeal cancer. Value for confirmation of N0 neck and detection of occult metastases. Oral Oncol. 2008, 44 (1): 31-36. 10.1016/j.oraloncology.2006.12.003.CrossRefPubMed
35.
Ng SH, Yen TC, Liao CT, Chang JT, Chan SC, Ko SF, Wang HM, Wong HF: 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J Nucl Med. 2005, 46 (7): 1136-1143.PubMed
36.
Platzek I, Beuthien-Baumann B, Schneider M, Gudziol V, Langner J, Schramm G, Laniado M, Kotzerke J, van den Hoff J: PET/MRI in head and neck cancer: initial experience. Eur J Nucl Med Mol Imaging. 2013, 40 (1): 6-11. 10.1007/s00259-012-2248-z.CrossRefPubMed
37.
Boss A, Stegger L, Bisdas S, Kolb A, Schwenzer N, Pfister M, Claussen CD, Pichler BJ, Pfannenberg C: Feasibility of simultaneous PET/MR imaging in the head and upper neck area. Eur Radiol. 2011, 21 (7): 1439-1446. 10.1007/s00330-011-2072-z.CrossRefPubMed
Metadata
Title
Diagnostic value of retrospective PET-MRI fusion in head-and-neck cancer
Authors
Denys J Loeffelbein
Michael Souvatzoglou
Veronika Wankerl
Julia Dinges
Lucas M Ritschl
Thomas Mücke
Anja Pickhard
Matthias Eiber
Markus Schwaiger
Ambros J Beer
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-846

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Carnosine inhibits carbonic anhydrase IX-mediated extracellular acidosis and suppresses growth of HeLa tumor xenografts

Research article

Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma

Research article

A new technique combining virtual simulation and methylene blue staining for the localization of small peripheral pulmonary lesions

Study protocol

Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum 3rd trial)

Research article

Meta-analysis shows that circulating tumor cells including circulating microRNAs are useful to predict the survival of patients with gastric cancer

Research article

Cyr61 Expression is associated with prognosis in patients with colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits